Cerebral ischemia and neuroregeneration

Reggie H.C. Lee; Michelle H.H. Lee; Celeste Y.C. Wu; Alexandre Couto E Silva; Harlee E. Possoit; Tsung Han Hsieh; Alireza Minagar; Hung Wen Lin

doi:10.4103/1673-5374.228711

Cerebral ischemia and neuroregeneration

Reggie H.C. Lee, Michelle H.H. Lee, Celeste Y.C. Wu, Alexandre Couto E Silva, Harlee E. Possoit, Tsung Han Hsieh, Alireza Minagar, Hung Wen Lin

Neurology

Research output: Contribution to journal › Review article › peer-review

89 Scopus citations

Abstract

Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.

Original language	English (US)
Pages (from-to)	373-385
Number of pages	13
Journal	Neural Regeneration Research
Volume	13
Issue number	3
DOIs	https://doi.org/10.4103/1673-5374.228711
State	Published - Mar 2018

Keywords

Cerebral ischemia
Fatty acids
Melatonin
Neuromodulation therapy
Pifithrin-α
Protein kinase C
Resveratrol
Stem cell
Sympathetic nervous system
Traditional Chinese therapies

ASJC Scopus subject areas

Developmental Neuroscience

Access to Document

10.4103/1673-5374.228711

Cite this

@article{2b3d479bba6f47e8a9129d2f387ed7ef,

title = "Cerebral ischemia and neuroregeneration",

abstract = "Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.",

keywords = "Cerebral ischemia, Fatty acids, Melatonin, Neuromodulation therapy, Pifithrin-α, Protein kinase C, Resveratrol, Stem cell, Sympathetic nervous system, Traditional Chinese therapies",

author = "Lee, {Reggie H.C.} and Lee, {Michelle H.H.} and Wu, {Celeste Y.C.} and {Couto E Silva}, Alexandre and Possoit, {Harlee E.} and Hsieh, {Tsung Han} and Alireza Minagar and Lin, {Hung Wen}",

note = "Funding Information: 1R01NS096225-01A1, the American Heart Association grants AHA-13SDG1395001413, AHA-17GRNT33660336, AHA-17POST33660174, the Louisiana State University Grant in Aid research council, and The Malcolm Feist Cardiovascular Research Fellowship. Funding Information: manuscript critically for important intellectual content, and final approval. CYCW, ACS, HEP, THH: drafted manuscript and final approval. AM, and HWL: revised manuscript critically for important intellectual content and final approval. Conflicts of interest: None declared. Financial support: This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke grant 1R01NS096225-01A1, the American Heart Association grants AHA-13SDG1395001413, AHA-17GRNT33660336, AHA-17POST33660174, the Louisiana State University Grant in Aid research council, and The Malcolm Feist Cardiovascular Research Fellowship. Plagiarism check: Checked twice by iThenticate. Peer review: Externally peer reviewed. Open access statement: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Shar-eAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under identical terms. Open peer reviewer: Shasha Li, Harvard Medical School, USA. Publisher Copyright: {\textcopyright} 2018 Medknow Publications. All rights reserved.",

year = "2018",

month = mar,

doi = "10.4103/1673-5374.228711",

language = "English (US)",

volume = "13",

pages = "373--385",

journal = "Neural Regeneration Research",

issn = "1673-5374",

publisher = "Editorial Board of Neural Regeneration Research",

number = "3",

}

TY - JOUR

T1 - Cerebral ischemia and neuroregeneration

AU - Lee, Reggie H.C.

AU - Lee, Michelle H.H.

AU - Wu, Celeste Y.C.

AU - Couto E Silva, Alexandre

AU - Possoit, Harlee E.

AU - Hsieh, Tsung Han

AU - Minagar, Alireza

AU - Lin, Hung Wen

N1 - Funding Information: 1R01NS096225-01A1, the American Heart Association grants AHA-13SDG1395001413, AHA-17GRNT33660336, AHA-17POST33660174, the Louisiana State University Grant in Aid research council, and The Malcolm Feist Cardiovascular Research Fellowship. Funding Information: manuscript critically for important intellectual content, and final approval. CYCW, ACS, HEP, THH: drafted manuscript and final approval. AM, and HWL: revised manuscript critically for important intellectual content and final approval. Conflicts of interest: None declared. Financial support: This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke grant 1R01NS096225-01A1, the American Heart Association grants AHA-13SDG1395001413, AHA-17GRNT33660336, AHA-17POST33660174, the Louisiana State University Grant in Aid research council, and The Malcolm Feist Cardiovascular Research Fellowship. Plagiarism check: Checked twice by iThenticate. Peer review: Externally peer reviewed. Open access statement: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Shar-eAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under identical terms. Open peer reviewer: Shasha Li, Harvard Medical School, USA. Publisher Copyright: © 2018 Medknow Publications. All rights reserved.

PY - 2018/3

Y1 - 2018/3

N2 - Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.

AB - Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.

KW - Cerebral ischemia

KW - Fatty acids

KW - Melatonin

KW - Neuromodulation therapy

KW - Pifithrin-α

KW - Protein kinase C

KW - Resveratrol

KW - Stem cell

KW - Sympathetic nervous system

KW - Traditional Chinese therapies

UR - http://www.scopus.com/inward/record.url?scp=85049833023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049833023&partnerID=8YFLogxK

U2 - 10.4103/1673-5374.228711

DO - 10.4103/1673-5374.228711

M3 - Review article

AN - SCOPUS:85049833023

VL - 13

SP - 373

EP - 385

JO - Neural Regeneration Research

JF - Neural Regeneration Research

SN - 1673-5374

IS - 3

ER -

Cerebral ischemia and neuroregeneration

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this